3-Hydroxyphencyclidine (3-HPC), a breakdown product of phencyclidine (PCP), is increasingly attracting clinical focus due to initial data suggesting different biological properties. Current research suggest that 3-HPC may exhibit separate effects on the central system, arguably contributing to some of the unexpected manifestations associated with P